Investors

Corporate profile

Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606 (liposomal treprostinil inhalation suspension), an investigational sustained-release formulation of treprostinil administered twice-daily via rapid nebulization with a hand-held portable system, and currently markets generic Treprostinil Injection for the treatment of PAH in partnership with Sandoz, Inc.